GETEIN BIOTECH, INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.62 CNY | -0.58% |
|
-3.25% | -21.64% |
| Apr. 29 | Getein Biotech, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 29 | Getein Biotech, Inc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 1.82B 251M | Sales 2023 | 1.37B 189M | Capitalization | 5.58B 770M |
|---|---|---|---|---|---|
| Net income 2022 | 499M 68.85M | Net income 2023 | 280M 38.63M | EV / Sales 2022 | 3.17 x |
| Net cash position 2022 | 566M 78.15M | Net cash position 2023 | 270M 37.19M | EV / Sales 2023 | 3.88 x |
| P/E ratio 2022 |
12.8
x | P/E ratio 2023 |
20
x | Employees | 2,508 |
| Yield 2022 |
2.72% | Yield 2023 |
-
| Free-Float | 52.62% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.58% | ||
| 1 week | -3.25% | ||
| Current month | -4.43% | ||
| 1 month | -8.20% | ||
| 3 months | -4.22% | ||
| 6 months | -26.45% | ||
| Current year | -21.64% |
1 week
8.59
9.06
1 month
8.5910.09
Current year
7.4411.17
1 year
7.4413.23
3 years
7.4418.59
5 years
7.4423.69
10 years
7.4423.69
| Managers | Title | Age | Since |
|---|---|---|---|
En Ben Su
CEO | Chief Executive Officer | 58 | 02-03-07 |
Wen Ni
DFI | Director of Finance/CFO | 41 | 12-12-31 |
Gang Zhu
BRD | Director/Board Member | 38 | 11-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
En Ben Su
CEO | Chief Executive Officer | 58 | 02-03-07 |
Bin Yan
BRD | Director/Board Member | 42 | 09-12-31 |
En Kui Su
BRD | Director/Board Member | 62 | 01-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 12 M€ | -16.71% | - | |
| 0.00% | 112 M€ | +5.18% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-04 | 8.62 | -0.58% | 2 865 293 |
| 24-06-04 | 8.67 | -0.91% | 3,266,218 |
| 24-06-03 | 8.75 | -2.99% | 4,094,129 |
| 24-05-31 | 9.02 | +0.78% | 2,146,496 |
| 24-05-30 | 8.95 | +0.67% | 2,588,392 |
End-of-day quote Shanghai S.E., June 04, 2024
More quotes
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -21.64% | 607M | |
| -5.37% | 12.35B | |
| -3.75% | 8.17B | |
| +7.79% | 5.77B | |
| +33.10% | 5.65B | |
| -12.12% | 4.1B | |
| +14.18% | 2.67B | |
| -5.70% | 2.31B | |
| +18.60% | 2.02B | |
| -6.70% | 1.81B |
- Stock Market
- Equities
- 603387 Stock
